E-slide Library

Biologic therapies in ulcerative colitis (UC) patients

Faculty

Bret Lashner, MD
Director of the Center for Inflammatory Bowel Disease
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Biography

Introduction

The accepted treatment algorithm for ulcerative colitis (UC) is a step-wise approach commencing with 5-ASAs and moving on to biologic therapies when necessary. Earlier intervention, and prompt "step-up" therapy when indicated has been shown to improve long-term response to therapy. This IBD Dialog will provide an overview of the biologic therapies currently available for UC, focusing on when biologic therapy should be initiated, and looking at some of the key differences between the two different classes currently available, anti-TNFs and anti-integrins.

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release date: November 4, 2015

Learning objectives

After completing this activity, the participant should be better able to:

  • Summarize the evidence for the appropriate initiation and sequencing of biologic therapy in UC
  • Describe some of the key differences between the biologic therapies available for treatment of UC
  • Explain the factors to consider before and during biologic therapy in terms of patient preparation and monitoring
  • Provide appropriate care and counsel for patients and their families.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

View Presentation